ReviewInflammatory bowel diseases2022
Early Diagnosis, Early Stratification, and Early Intervention to Deliver Precision Medicine in IBD.
Review in Inflammatory bowel diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Second United Arab Emirates consensus guidance on the diagnosis and management of inflammatory bowel disease.World journal of gastroenterology · 2025Pooled it
- Predicting outcomes for Crohn's disease using a molecular biomarker: profile trial.Clinical medicine (London, England) · 2022Trial
- Paradigm shift in inflammatory bowel disease management-advanced therapy utilization, persistence, and outcomes in a United Arab Emirates cohort during 2015-2025.Crohn's & colitis 360 · 2026Article
- Therapy Persistence and Dose Escalation of Advanced Treatments in First and Second Line of Ulcerative Colitis and Crohn's Disease - A Retrospective Cohort Analysis of Healthcare Claims Data.Zeitschrift fur Gastroenterologie · 2026Article
- Mucuna pruriens extract as prebiotic and Lactobacillus rhamnosus as probiotic intervention mitigated histological changes in DNCB-induced colitis via GLP-1/Nrf2/NF-κB axis regulation.Journal of molecular histology · 2026Article
- Recent Advances in Exploring Casein Peptide Regulation of Inflammatory Bowel Disease from an Intestinal Barrier Perspective: Correlations, Mechanisms, Challenges and Solutions.Foods (Basel, Switzerland) · 2026Review
- Redefining Early Intervention and the Window of Opportunity in Crohn's Disease.Gastroenterology & hepatology · 2026Article
- Decoding non-coding SNPs: systems genomics modelling dissects the heterogeneity of IBD.Molecular systems biology · 2026Article
- Article
- The Dedicated Inflammatory Bowel Disease Nurse, If You Know Them, You Love Them: Survey of the Italian IBD Patients' Association.Crohn's & colitis 360 · 2025Article
- Identification of key genes as diagnostic biomarkers for IBD using bioinformatics and machine learning.Journal of translational medicine · 2025Article
- Inflammatory Bowel Disease Advice Lines: A Scoping Review.Crohn's & colitis 360 · 2025Article
- FastColitisDetector-XAI: An efficient AI model utilizing sparse Autoencoder with explainable AI for ulcerative colitis diagnosis.MethodsX · 2025Article
- Neutrophil Elastase and Elafin in Inflammatory Bowel Diseases: Urinary Biomarkers Reflecting Intestinal Barrier Dysfunction and Proteolytic Activity.Journal of clinical medicine · 2025Article
- Role of 5-aminosalicylic acid in ulcerative colitis management in 8 Asian territories: a physician survey.Intestinal research · 2025Article
- Electronic Health Records-based identification of newly diagnosed Crohn's Disease cases.Artificial intelligence in medicine · 2025Article
- Early subclinical stages of the inflammatory bowel diseases: insights from human and animal studies.American journal of physiology. Gastrointestinal and liver physiology · 2025Review
- Machine Learning of Serum Cytokine and Chemokine Profiles Can Classify Inflammatory Bowel Disease Beyond Clinical Diagnosis.Gastro hep advances · 2025Article
- Risk factor analysis and predictive model development for healthcare-associated infections post-coronary artery bypass grafting.Frontiers in public health · 2025Article
- Plasma protein-based and polygenic risk scores serve complementary roles in predicting inflammatory bowel disease.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Despite huge advances in understanding the molecular basis of IBD, clinical management has continued to rely on a "trial and error" approach. In addition, a therapeutic ceiling has emerged whereby even the most effective interventions are only beneficial for approximately 30% of patients. Consequently, several tools have been developed to aid stratification and guide treatment-decisions. We review the potential application for many of these precision medicine approaches, which are now almost within reach. We highlight the importance of early action (and avoiding inaction) to ensure the best outcomes for patients and how combining early action with precision tools will likely ensure the right treatment is delivered at the right time and place for each individual person living with IBD. The lack of clinical impact to date from precision medicine, despite much hype and investment, should be tempered with the knowledge that clinical translation can take a long time, and many promising breakthroughs might be ready for clinical implementation in the near future. We discuss some of the remaining challenges and barriers to overcome for clinical adoption. We also highlight that early recognition, early diagnosis, early stratification, and early intervention go hand in hand with precision medicine tools. It is the combination of these approaches that offer the greatest opportunity to finally deliver on the promise of precision medicine in IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.